Nuvation Bio is projected to report third-quarter consensus revenue of $34.39 million and a loss per share of $0.12, with its current stock price of $4.76 trading well below the average analyst price target of $13.22. The primary story for investors this quarter is the commercial launch trajectory and market uptake of IBTROZI (taletrectinib) in the ROS1-positive non-small cell lung cancer market.
Following its recent FDA approval and label expansion, IBTROZI is expected to drive a 162.1% year-over-year revenue surge as the company transitions into a commercial-stage oncology player. Beyond sales performance, investors are also looking for pipeline updates regarding the Phase 3 SIGMA study of safusidenib and the company's remaining cash runway for further clinical development.